Our discovery from innovative laboratory research has led to the identification of R-roscovitine, a selective CDK inhibitor with dual effect suppressing both cell proliferation and ACTH production in pituitary corticotroph tumors. We now propose a pilot, proof of concept phase II clinical trial to treat with R-roscovitine of patiens with corticotroph tumors (Cushing disease), who are recruited from the Pituitary Center at Cedars-Sinai Medical Center, to determine if R-roscovitine can safely normalize urinary free cortisol levels by reducing pituitary corticotroph tumor ACTH production. R-roscovitine has been undergoing phase I and II clinical trials for several malignancies, and, if effective for corticotrph tumors, its oral dosing route and relatively mild side effects make daily long-term treatment of Cushing disease feasible. Our study will explore a novel intervention for much needed pharmaco-therapeutic strategies directly targeting pituitary corticotroph tumors, one of the most challenging human neuroendocrine diseases.

Public Health Relevance

We have identified a small molecule CDK2/cyclin E inhibitor, R-roscovitine, which has a dual action suppressing both cell proliferation and ACTH production in pituitary corticotroph tumors. By performing the proposed pilot, proof of concept phase II clinical trial with R-roscovitine, we will test a new and unique intervention directly targeting corticotroph tumors in patients with Cushing disease. Data collected from the proposed study will serve as a basis of developing a future R01 grant application for a full-scale clinical trial.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Malozowski, Saul N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cedars-Sinai Medical Center
Los Angeles
United States
Zip Code
Araki, Takako; Liu, Ning-Ai (2018) Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease. Front Endocrinol (Lausanne) 9:444
Günther, Thomas; Tulipano, Giovanni; Dournaud, Pascal et al. (2018) International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 70:763-835
Araki, Takako; Liu, Xiaohai; Kameda, Hiraku et al. (2017) EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis. J Endocr Soc 1:127-143
Recouvreux, M Victoria; Wu, J Boyang; Gao, Allen C et al. (2017) Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. Endocrinology 158:2255-2268
Araki, Takako; Liu, Ning-Ai; Tone, Yukiko et al. (2016) E2F1-mediated human POMC expression in ectopic Cushing's syndrome. Endocr Relat Cancer 23:857-870
Chesnokova, Vera; Zonis, Svetlana; Zhou, Cuiqi et al. (2016) Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci U S A 113:E3250-9
Melmed, Shlomo (2016) Pituitary Medicine From Discovery to Patient-Focused Outcomes. J Clin Endocrinol Metab 101:769-77
Rogatko, André; Cook-Wiens, Galen; Tighiouart, Mourad et al. (2015) Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding. Entropy (Basel) 17:5288-5303
Melmed, Shlomo (2015) Pituitary tumors. Endocrinol Metab Clin North Am 44:1-9
Melmed, Shlomo (2015) Fertility and fragrance: another cause of Kallmann syndrome. J Clin Invest 125:2275-8

Showing the most recent 10 out of 12 publications